Engineered caspases directly rewire mutant Ras to cell death
Lukas MoelleriD, Andrew C. LuiD, Kevin Ho, Evan Zhang, Michael B. ElowitziD
Abstract
As central executioners of cell death, caspases that activate exclusively in diseased cells would provide powerful and specific therapeutic agents. Natural caspase regulation exhibits two universal features that facilitate the engineering of such caspases: proximity-induced subunit assembly and modular separation of substrate recruitment from catalysis. Here, we take advantage of these features to engineer "Raspases," split effector caspases that conditionally reconstitute active complexes upon detection of mutant Ras, an oncogene altered in roughly a quarter of all cancers. When delivered as mRNA in lipid nanoparticles, Raspases selectively eliminate Ras-mutant human cancer lines while sparing wild-type cells. The system is built entirely from human protein domains, can be encoded as a single polyprotein, and can be adapted to trigger pyroptosis. Critically, Raspases match or exceed the potency of alternative Ras-targeting interventions in vitro. These results establish retargeted caspases as a generalizable sense-and-kill platform for selective elimination of diseased cells.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Engineered protein circuits for cancer therapy
Andrew C. Lu, Lukas Moeller, … Michael B. Elowitz·bioRxiv·Apr 16, 2025
- Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RAS
V. Vidimar, G. L. Beilhartz, … K. J. Satchell·bioRxiv·Dec 17, 2019
- Selective targeting of an oncogenic KRAS mutant allele by CRISPR/Cas9 induces efficient tumor regression
Qianqian Gao, Wenjie Ouyang, … Cheng‐Chi Chao·TheranosticsPeer-reviewed·Jan 1, 2020
- Engineered subtilisin protease degrades active KRAS in cancer cells, leading to differential cell targeting
M.E. Goldstein, Betty Chu, … Thomas R. Fuerst·bioRxiv·Mar 6, 2026
- RAS specific protease Induces Irreversible Growth Arrest via p27 in several KRAS Mutant Colorectal Cancer cell lines
C. K. Stubbs, M. Biancucci, … K. J. F. Satchell·bioRxiv·Dec 8, 2020
- Engineering protein-specific proteases: targeting active RAS
Y. Chen, E. A. Toth, … P. N. Bryan·bioRxiv·Sep 21, 2020